Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes. [electronic resource]
Producer: 20200626Description: e250-e256 p. digitalISSN:- 2325-8179
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Bevacizumab -- administration & dosage
- Choroidal Neovascularization -- diagnostic imaging
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Humans
- Intravitreal Injections
- Male
- Ranibizumab -- administration & dosage
- Receptors, Vascular Endothelial Growth Factor -- administration & dosage
- Recombinant Fusion Proteins -- administration & dosage
- Recurrence
- Retrospective Studies
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Visual Acuity -- physiology
- Wet Macular Degeneration -- diagnostic imaging
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.